Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06928246 · ClinicalTrials.gov registry record · Phase 1
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis (AD), sponsored by Daniel Kaplan.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT06928246: Recruiting Phase 1 study of Atopic Dermatitis (AD), sponsored by Daniel Kaplan.
NCT06928246 is a Phase 1 study of Atopic Dermatitis (AD) that is actively recruiting participants, run by Daniel Kaplan. The registered enrollment target is 8 participants, below the 109-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06928246, a Phase 1 study of Atopic Dermatitis (AD), is actively recruiting participants, sponsored by Daniel Kaplan.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
Primary Outcome
Eczema Area and Severity Index (EASI) total score from 0-72, with higher score indicating more severity. The EASI index assigns proportionate values to 4 body regions. Each region is assigned a score of 0 to 3, indicating none, mild, moderate, and severe clinical expression. The percentage of area involved is also assigned an eruption proportional score from 0 to 6. The total body score for each body region is obtained by multiplying the sum of the severity scores by the area score, then multipl
Conditions Studied
Interventions
- DRUG Onabotulinum Toxin Type A - Phase 1b
- DRUG Onabotulinum Toxin Type A - Phase 2
Study Locations (2)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
- UPMC Department of Dermatology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-07-17 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT06928246 shows while recruiting
NCT06928246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 109-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 2 interventions - of which Onabotulinum Toxin Type A - Phase 1b is the first listed.
NCT06928246 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06928246 about?
NCT06928246 is a clinical study titled "The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis". The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
What is the current status of trial NCT06928246?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-07-17. Estimated completion is 2027-01.
What conditions does trial NCT06928246 study?
This clinical trial studies the following conditions: Atopic Dermatitis (AD).
What interventions are being tested in trial NCT06928246?
The interventions under investigation include: Onabotulinum Toxin Type A - Phase 1b (DRUG), Onabotulinum Toxin Type A - Phase 2 (DRUG).
Who is sponsoring clinical trial NCT06928246?
This trial is sponsored by Daniel Kaplan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06928246 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
RECRUITING · Phase 1
-
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
RECRUITING · Phase 1
-
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
ACTIVE NOT RECRUITING · Phase 1
-
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 1
-
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI